Expand AIM Menu
AIM MENU

AIM Stock Summary and Trading Ideas (Aim Immunotech | AMEX:AIM)

Charts for Today's Stock Price and Implied Volatility in Aim Immunotech

21-Jun-2024

Stock Price & Volume | Full Chart

Sentiment

Trading Statistics

Key Ratios

Aim Immunotech (AIM) Frequently Asked Questions

What does Aim Immunotech do?

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

What symbol and exchange does Aim Immunotech stock trade?

Aim Immunotech trades on the AMEX stock market under the symbol AIM.

What is Aim Immunotech stock price doing today?

As of June 21, 2024, AIM stock price climbed to $0.41 with 270,251 million shares trading.

What is Aim Immunotech's Beta?

AIM has a beta of 1.58, meaning it tends to be more sensitive to market movements. AIM has a correlation of 0.06 to the broad based SPY ETF.

How much is Aim Immunotech worth?

AIM has a market cap of $23.45 million. This is considered a Sub-Micro Cap stock.

What is the highest and lowest price Aim Immunotech traded in the last 3 year period?

In the last 3 years, AIM stock traded as high as $2.22 and as low as $.29.

What are the top ETFs holding Aim Immunotech?

The top ETF exchange traded funds that AIM belongs to (by Net Assets): VTI, VXF.

Is Aim Immunotech (AIM) a good investment?

AIM has underperformed the market in the last year with a price return of -21.0% while the SPY ETF gained +26.8%. However, in the short term, AIM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.7% vs +4.6% return in SPY. But in the last 2 weeks, AIM shares have been beat by the market, returning -3.4% compared to an SPY return of +2.3%.

What is the support and resistance for Aim Immunotech (AIM) stock price?

AIM support price is $.37 and resistance is $.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AIM stock will trade within this expected range on the day.